Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels - Clinical significance of interleukin-l0 serum levels for Hodgkin's disease

被引:78
作者
Bohlen, H
Kessler, M
Sextro, M
Diehl, V
Tesch, H
机构
[1] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany
[2] Univ Cologne, Dept Diagnost Radiol, D-50931 Cologne, Germany
关键词
cytokine; Hodgkin's disease; IL-10; serum; prognostic marker;
D O I
10.1007/s002770050564
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interleukin (IL)-10 is a pleiotropic cytokine with potent inhibitory effects Cowards T-H-1 cells. IL-10 inhibits secretion of IL-2 and interferon (IFN)gamma by T cells and downregulates major histocompatibility complex antigens, A variety of tumor cells secrete IL-10, which can inhibit growth of tumor-specific cytotoxic T cells. IL-10 expression has also been detected in B-cell lymphomas and Hodgkin's disease (HD), and it has been suggested that the cytokine is involved in the pathogenesis of these tumors. We analyzed levels of IL-10 in pretreatment sera of 64 patients with HD and healthy controls using a sensitive enzyme-linked immunosorbent assay. Patients with biopsy-proven HD were enrolled in trials of the German Hodgkin Study Group (GHSG). Elevated IL-10 levels were detected in the sera of nine patients with HD (14.1%) (range 4.5-225.6 pg/ml with a mean of 61.5 pg/ml). IL-10 was not detectable in a control population of healthy volunteers (n = 90). Multivariate analyses revealed a significant correlation between elevated IL-10 levels and higher age (over 45 years) but not with any other factors defined by the international prognostic factor score. Patients with elevated IL-10 levels had a significantly lower freedom from treatment failure rate as detected in univariate and multivariate tests. Thus, IL-10 may serve as an independent prognostic factor for HD patients.
引用
收藏
页码:110 / 113
页数:4
相关论文
共 13 条
  • [1] LYMPHOTOXIN, TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-6 GENE TRANSCRIPTS ARE PRESENT IN HODGKIN AND REED-STERNBERG CELLS OF MOST HODGKINS-DISEASE CASES
    FOSS, HD
    HERBST, H
    OELMANN, E
    SAMOL, J
    GREBE, M
    BLANKENSTEIN, T
    MATTHES, J
    QIN, ZH
    FALINI, B
    PILERI, S
    DIAMANTSTEIN, T
    STEIN, H
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (04) : 627 - 635
  • [2] LOCAL SUPPRESSION OF EPSTEIN-BARR-VIRUS (EBV)-SPECIFIC CYTOTOXICITY IN BIOPSIES OF EBV-POSITIVE HODGKINS-DISEASE
    FRISAN, T
    SJOBERG, J
    DOLCETTI, R
    BOIOCCHI, M
    DE RE, V
    CARBONE, A
    BRAUTBAR, C
    BATTAT, S
    BIBERFELD, P
    ECKMAN, M
    OST, O
    CHRISTENSSON, B
    SUNDSTROM, C
    BJORKHOLM, M
    PISA, P
    MASUCCI, MG
    [J]. BLOOD, 1995, 86 (04) : 1493 - 1501
  • [3] A prognostic score for advanced Hodgkin's disease
    Hasenclever, D
    Diehl, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1506 - 1514
  • [4] Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease
    Herbst, H
    Foss, HD
    Samol, J
    Araujo, I
    Klotzbach, H
    Krause, H
    Agathanggelou, A
    Niedobitek, G
    Stein, H
    [J]. BLOOD, 1996, 87 (07) : 2918 - 2929
  • [5] AUTOCRINE AND PARACRINE FUNCTIONS OF CYTOKINES IN MALIGNANT-LYMPHOMAS
    HSU, SM
    HSU, PL
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 1994, 48 (10) : 433 - 444
  • [6] PRODUCTION OF MULTIPLE CYTOKINES BY HODGKINS-DISEASE DERIVED CELL-LINES
    KLEIN, S
    JUCKER, M
    DIEHL, V
    TESCH, H
    [J]. HEMATOLOGICAL ONCOLOGY, 1992, 10 (06) : 319 - 329
  • [7] KRETSCHMER C, 1990, AM J PATHOL, V137, P341
  • [8] INTERLEUKIN-10
    MOORE, KW
    OGARRA, A
    MALEFYT, RD
    VIEIRA, P
    MOSMANN, TR
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 : 165 - 190
  • [9] PROPERTIES AND FUNCTIONS OF INTERLEUKIN-10
    MOSMANN, TR
    [J]. ADVANCES IN IMMUNOLOGY, VOLUME 56, 1994, 56 : 1 - 26
  • [10] HUMAN AND VIRAL INTERLEUKIN-10 IN HODGKINS-DISEASE, AND ITS INFLUENCE ON CD4(+) AND CD8(+) T-LYMPHOCYTES
    OHSHIMA, K
    SUZUMIYA, J
    AKAMATU, M
    TAKESHITA, M
    KIKUCHI, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (01) : 5 - 10